Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
gg9DaebYFnQx2qRm
